1. Aronson, J. K. (2006). Rare diseases and orphan drugs. British Journal of Clinical Pharmacology, 61(3), 243–245. https://doi.org/10.1111/j.1365-2125.2006.02617.x. Accessed October 7, 2015, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1885017/
2. Brains for Brain Foundation. (2014). Dr Horst Schmidt Klinik. Healthcare transition of adolescent rare disease patients (Position Paper 2014). Accessed September 18, 2015, from https://www.innermed.eu/uploads/assets/6_BfB_Transition_Paper_Final_03022015.pdf
3. Byskov Holm, B., & Jensen, L. (2014). Only the strong survive—Said by a mother navigating the welfare systems. Rare Diseases Denmark. Accessed September 18, 2015, from https://www.rare-diseases.eu/wp-content/uploads/2013/08/12_t1.pdf
4. de Chalendar, M., Bee, S., Olry, A., & Rath, A. (2014). Appraisal of disability in rare diseases with the ICF-CY: The Orphanet disability project. Archives of Disease in Childhood, 99(Suppl 2), A14–A15.
5. Commission Expert Group on Rare Diseases. (2016). Recommendations to support the incorporation of rare diseases into social services and policies. Accessed September 21, 2017, from https://ec.europa.eu/health//sites/health/files/rare_diseases/docs/recommendations_socialservices_policies_en.pdf